Announcement • Apr 07
ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs ABION announced that its next-generation immuno-oncology candidate, ABN202, demonstrated a superior anti-cancer mechanism compared with TROP2-targeting antibody-drug conjugates (ADCs) in preclinical studies. The findings will be presented as a poster at the American Association for Cancer Research (AACR 2026), to be held April 17–22 in San Diego, USA. ABN202 is a next-generation immuno-oncology drug candidate based on the company’s proprietary iRAC (Interferon-ß Antibody Conjugate) platform, designed to enable both direct tumor cell killing and robust immune activation. In the study, ABN202 demonstrated a superior anti-cancer mechanism compared with currently approved TROP2-targeting ADCs. Notably, ABN202 overcame resistance to TROP2-targeting ADCs and showed superior anti-tumor efficacy compared with ADCs combined with anti-PD-1 immune checkpoint inhibitors in preclinical models. In addition, ABN202 induced sustained and systemic CD8-positive T cell-mediated immune responses, suggesting the potential for durable anti-tumor immunity. These findings suggest that ABN202 represents a novel immuno-oncology strategy capable of overcoming resistance associated with existing ADC therapies, highlighting its strong potential as a new treatment option for patients with solid tumors who have failed prior ADC-based therapies. ABION’s first-in-class iRAC platform can be applied not only to TROP2-targeting antibodies but also to a broad range of solid tumor targets. This platform's versatility positions iRAC as a promising next-generation immuno-oncology approach with potential pipeline expansion opportunities. Announcement • Mar 14
ABION Inc., Annual General Meeting, Mar 27, 2026 ABION Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 437, dorimcheon-ro, yeongdeungpo-gu, seoul South Korea New Risk • Jan 19
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 75% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 6.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Revenue is less than US$1m (₩1.0b revenue, or US$700k). 
